Related Experiment Video

Updated: Jun 27, 2025

In Vivo Investigation of Antimicrobial Blue Light Therapy for Multidrug-resistant Acinetobacter baumannii Burn Infections Using Bioluminescence Imaging
09:29

In Vivo Investigation of Antimicrobial Blue Light Therapy for Multidrug-resistant Acinetobacter baumannii Burn Infections Using Bioluminescence Imaging

Published on: April 28, 2017

9.3K

Multidrug-Resistant Organisms: The Silent Plight of Burn Patients

Randa Elsheikh1, Abdelrahman M Makram2

  • 1Deanery of Biomedical Sciences at Edinburgh Medical School, University of Edinburgh, Edinburgh EH8 9YL, UK.

Journal of Burn Care & Research : Official Publication of the American Burn Association
|May 2, 2024
PubMed

Insights

Multidrug-resistant organisms (MDROs) pose a significant threat, especially to burn patients with weakened immunity. This review focuses on MDROs in burn care, discussing treatments and emphasizing antibiotic stewardship.

Area of Science:

  • Infectious Diseases
  • Critical Care Medicine
  • Burn Management

Background:

  • The global rise of multidrug-resistant organisms (MDROs) presents a critical challenge to healthcare systems worldwide.
  • Burn patients are particularly vulnerable to severe infections due to their hypermetabolic state and compromised immune barriers.
  • These patients face risks similar to those with prolonged hospitalization, including ventilator-associated pneumonia and urinary tract infections.

Purpose of the Study:

  • To review current knowledge on multidrug resistance in infections.
  • To focus specifically on the challenges posed by MDROs in patients with burns.
  • To discuss causative organisms, treatment strategies, and the importance of antibiotic stewardship.

Main Methods:

  • Literature review of current research on multidrug resistance.
  • Analysis of infection risks and causative organisms in burn patients.
  • Discussion of established and emerging treatment options and preventative strategies.

Main Results:

  • Burn patients are at high risk for hyperinfection due to compromised immunity and hypermetabolism.
  • Common hospital-acquired infections like VAP and UTIs are exacerbated by MDROs in this population.
  • Consensus on management strategies is discussed, highlighting areas of agreement and ongoing debate.

Conclusions:

  • Effective management of MDROs in burn patients requires a multidisciplinary approach.
  • Antibiotic stewardship programs are crucial for combating the spread of resistance.
  • Teamwork and adherence to best practices are essential for controlling MDRO outbreaks in vulnerable patient groups.
Keywords:
burninfection controlmultidrug-resistant organisms

More Related Videos

Rat Burn Model to Study Full-Thickness Cutaneous Thermal Burn and Infection08:40

Rat Burn Model to Study Full-Thickness Cutaneous Thermal Burn and Infection

Published on: August 23, 2022

4.8K
Multiplex Therapeutic Drug Monitoring by Isotope-dilution HPLC-MS/MS of Antibiotics in Critical Illnesses11:17

Multiplex Therapeutic Drug Monitoring by Isotope-dilution HPLC-MS/MS of Antibiotics in Critical Illnesses

Published on: August 30, 2018

12.9K

Related Concept Videos

Burn Injuries01:22

Burn Injuries

Burn injuries occur when the skin and underlying tissues are damaged due to exposure to heat, electricity, chemicals, radiation, or friction. They can vary in severity, from minor superficial burns to severe deep burns that can be life-threatening.
The damage results in the death of skin cells, which can lead to a massive loss of fluid. Dehydration, electrolyte imbalance, and renal and circulatory failure follow, which can be fatal. Burn patients are treated with intravenous fluids to offset...
2.5K
Defense Against Bacterial Pathogens01:31

Defense Against Bacterial Pathogens

The human immune system is a complex network of cells, tissues, and organs that work together to defend the body against bacterial infections. It consists of various immune cells, each playing a specific role in the defense mechanism.
Phagocytes
Phagocytes are the frontline soldiers of the immune system. They include neutrophils and macrophages. Neutrophils are the most abundant type of white blood cell and are quickly mobilized to the site of infection. Macrophages are larger cells that patrol...
1.4K
Pulmonary Tuberculosis V01:28

Pulmonary Tuberculosis V

Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
178
Pulmonary Tuberculosis I01:29

Pulmonary Tuberculosis I

Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
241
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
Pneumonia IV: Management01:28

Pneumonia IV: Management

The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
323